Bibliography
- Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011;91:1161-218
- Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600
- Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7
- Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009;11:e22
- Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009;41:1303-7
- Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308-12
- Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010;11:791-7
- Vancraenenbroeck R, Lobbestael E, De Maeyer M, et al. Kinases as targets for Parkinson's disease; from genetics to therapy. CNS Neurol Disord Drug Targets 2011;10:724-40
- Kethiri RR, Bakthavatchalam R. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011–2013). Expert Opin Ther Pat 2014;24:745-57
- Deng X, Choi HG, Buhrlage SJ, et al. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). Expert Opin Ther Pat 2012;22:1415-26
- Baptista MA, Dave KD, Frasier MA, et al. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One 2013;8:e80705
- Herzig MC, Kolly C, Persohn E, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 2011;20:4209-23
- Dzamko N, Deak M, Hentati F, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 2010;430:405-13
- Lobbestael E, Zhao J, Rudenko IN, et al. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J 2013;456:119-28
- Daniëls V, Baekelandt V, Taymans JM. On the Road to Leucine-Rich Repeat Kinase 2 Signalling: evidence from Cellular and in vivo Studies. Neurosignals 2011;19:1-15
- Ramonet D, Daher JP, Lin BM, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011;6:e18568
- Chen CY, Weng YH, Chien KY, et al. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 2012;19:1623-33
- Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010;16:998-1000
- Dusonchet J, Kochubey O, Stafa K, et al. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci 2011;19;31:907-12
- Burke RE, O'Malley K. Axon degeneration in Parkinson's disease. Exp Neurol 2013;246:72-83